Last reviewed · How we verify
Post-transplant cytomegalovirus infection
Approved treatments
- Livtencity · Takeda
Livtencity works by inhibiting the pUL97 kinase enzyme, which is essential for the replication of cytomegalovirus.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Post-transplant cytomegalovirus infection patent landscape — cliff calendar, originator estates, attackable patents
- Post-transplant cytomegalovirus infection treatment landscape brief
- Post-transplant cytomegalovirus infection treatment updates RSS
Frequently asked questions about Post-transplant cytomegalovirus infection
What drugs treat Post-transplant cytomegalovirus infection?
Tracked treatments include Livtencity.
What is the treatment for Post-transplant cytomegalovirus infection?
Standard treatment for Post-transplant cytomegalovirus infection includes Livtencity. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Post-transplant cytomegalovirus infection patent cliff · Post-transplant cytomegalovirus infection CI report
- Treatment: Livtencity · Takeda
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing